A naukri.com initiative
Bioengineer
2w
155
Image Credit: Bioengineer
Linker-Free PROTACs Drive Efficient Oncoprotein Degradation
- A recent study in Nature Communications introduces a novel approach with linker-free PROTACs for efficient oncoprotein degradation, offering a transformative strategy in cancer therapy.
- Linker-free PROTACs simplify molecular technology by eliminating the traditional linker, enhancing pharmacokinetics, synthetic ease, and cellular permeability.
- These PROTACs facilitate induced proximity between oncoproteins and cellular degradation machinery, overcoming drug resistance issues stemming from target mutations.
- Research by Zhang et al. demonstrated efficient and selective degradation of oncoproteins in cancer cell lines, with the potency often exceeding that of linker-containing analogs.
- Structural characterization elucidates how linker-free PROTACs form stable ternary complexes conducive to ubiquitination, enhancing binding affinity and cooperative interactions.
- The design's modularity allows targeting diverse E3 ligases, expanding therapeutic possibilities and potentially reducing off-target toxicity.
- Pharmacological profiling in animal models showed promising results with significant tumor regression and improved pharmacokinetic properties of linker-free PROTACs.
- The study's impact extends beyond oncology, paving the way for applications in neurodegeneration, autoimmunity, and viral diseases, leveraging precision proteolysis for targeted therapy.
- While showcasing promise, challenges like chemistry intricacies and safety evaluations remain before linker-free PROTACs can progress to human clinical trials.
- The study propels the field towards innovative drug discovery by charting a new course that harmonizes potency, selectivity, and drug-like properties in next-generation PROTACs.
Read Full Article
9 Likes
For uninterrupted reading, download the app